u/joaquin_trevino

Cosigning that protein gets harder precisely when appetite drops. That is the actual difficulty and it is logistical.

vendor, compound, batch, service, result — that is the template

PCOS and insulin resistance are the thread that runs through this board

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

I would not post that as a finding. It is a single result and the template asks you to say so.

Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

Cosigning on fertility changing with weight loss. It catches people who were not expecting it at all.

daily dosing changes adherence in both directions

Cosigning on timeframe. "18kg" means something completely different over 17 months than over one.

Yes. The middle is where everybody actually lives and almost nobody posts from it.

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

Not convinced by the comparison. Different services, different gradients, and you are treating one as ground truth.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

Stopped reading the fastest posts here for a month and my mood improved considerably.

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

This is the split the whole board depends on. Authorisation is European; payment is national.

nothing on this board is a training or nutrition prescription

Right, and the payoff arrives around month six when a pattern becomes visible that nobody could hold in their head.

A supply notice in one member state made the front page here and had no effect at all where I am.

pack sizes differ, so per-month comparisons need care

Same. Volume over novelty. Changing programme every six weeks cost me a year.

Yes. The middle is where everybody actually lives and almost nobody posts from it.

edit_for_clarity is right that the band matters more than the peak.

Disagreeing with this line: that gap is ordinary variance, not a contradiction between the lab and the certificate.

Correction: that is the authorisation position, and the question was about reimbursement. Different bodies, different answers.

Correcting myself upthread: I gave the completer figure and labelled it intention-to-treat.

the confidence interval is the finding, the point estimate is the headline

Agreed. And the interval, not the point estimate, is what the trial actually established.

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

a shortage in one member state is not a shortage in all of them

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.

inter-lab variance runs a point or two, plan your outrage accordingly